Abbott's Molecular Dx Unit Untouched as GE Plans to Buy In Vitro, POC Segments for $8B | GenomeWeb
NEW YORK (GenomeWeb News) — General Electric late yesterday said it plans to acquire two of Abbott Technologies’ diagnostics businesses for $8.13 billion in cash, and will leave alone the company’s molecular diagnostic unit.
 
The acquisition includes Abbott’s in vitro diagnostics and point-of-care divisions and represents another rung in GE Healthcare’s goal of creating a business that combines in vitro and in vivo technologies to diagnose diseases.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.